PharmaFocus Today – Page 132 – media

2025 medical device global exhibition summary

The medical device industry has always been a crucial component of the healthcare sector, with a series of significant offline exhibitions held annually to provide professionals with an opportunity to stay informed about the latest technologies and trends, establish business connections, and promote industry development. In 2025, the medical device field will once again welcome a series of notable exhibitions, offering a rare chance for professionals and medical technology enthusiasts alike. Below is a preliminary compilation of medical device exhibition information for 2025 by Drugdu.com, which we are now sharing with you: January Arab Health Jan. 27-30 Exhibitiors：4200 Dubai February MD&M West Feb. 4-6 Exhibitiors：700 California Medical Expo Feb. 15-17 Exhibitiors：750 Calcutta March Xi ‘an West International Medical Equipment Exhibition Mar. 6-8 Exhibitiors：1300 Xi’an CDMEE Mar. 7-9 Exhibitiors：1200 Chengdu CMEE Mar. 15-17 Exhibitiors：2000 Shandong MEDICAL FAIR INDIA Mar. 27-29 Exhibitiors：419 Greater Noida KIMES Mar. 20-23 Exhibitiors：1200 Seoul April CMEF ...
- Source: drugdu
- 487
- January 15, 2025
2025 Biopharmaceutical global exhibition summary

With the continuous innovation and development in the field of biopharmaceuticals, 2025 will continue to witness a series of industry-specific exhibitions. These exhibitions will provide an excellent opportunity for professionals in the biomedical field to explore the latest scientific research achievements, technological innovations, and industry trends. Whether you are involved in research, pharmaceuticals, biotechnology, or an entrepreneur seeking potential business opportunities, these exhibitions will offer you abundant insights and business prospects. Therefore, in this issue, Drugdu.com has compiled a summary of exhibition information for most of the pharmaceutical industry worldwide in 2025. January DUPHAT Jan. 7-9 Exhibitiors：1100 Dubai Pharmapack Jan. 22-23 Exhibitiors：268 Paris February Asia Pharma Expo Feb. 12-14 Exhibitiors：800 Dacca INTERPHEX Week Osaka Feb. 25-27 Exhibitiors：308 Osaka March Medical Japan Mar. 5-7 Exhibitiors：1400 Osaka Infarma Mar. 25-27 Exhibitiors：430 Madrid April Interphex US Apr. 1-3 Exhibitiors：460 New York CPhI Japan Apr. 9-11 Exhibitiors：712 Tokyo Korea Chem / Korea PHARM & BIO Apr. ...
- Source: drugdu
- 274
- January 15, 2025
IPO Radar | Losing 1 billion yuan in one year, Maiwei Biotechnology seeks A+H listing, how long can it survive relying on external “blood transfusion”?

Maiwei Biology (688062. SH) seems to have taken every step very accurately. This company, founded in May 2017, was listed on the Science and Technology Innovation Board on January 18, 2022. This success was not only due to the registration system reform at that time, but also closely related to the country’s encouragement policies for emerging industries such as science and technology innovation and biomedicine. In this context, Maiwei Biotechnology, like many other innovative pharmaceutical companies of the same period, has achieved its listing plan even without commercial products and revenue. In 2024, with the further implementation of the “National Nine Measures” policy, the A-share IPO market has ushered in a stricter review environment, leading to an overall market downturn. At the same time, due to the further relaxation of overseas listing policies for mainland enterprises and the listing conditions for Hong Kong stocks, it has stimulated the willingness ...
- Source: drugdu
- 348
- January 15, 2025
Johnson&Johnson’s new drug, Edatinib, has been approved for market in China | Medical Early Reference

NO.1 and Huang Medicine’s new lung cancer drug, Savotinib, have been approved for new indications On January 13th, the official website of the National Medical Products Administration (NMPA) of China announced that the application for the new indication of Savotinib tablets by Hehuang Pharmaceutical has been approved. Sevotinib is a highly selective oral MET inhibitor. According to a previous press release from Hehuang Pharmaceutical, the drug has been approved for the treatment of locally advanced or metastatic non-small cell lung cancer in adult patients with mesenchymal epithelial transition factor (MET) exon 14 mutation. Comment: Hehuang Pharmaceutical has made breakthroughs in the field of innovative drugs in recent years. At the beginning of the year, the company transferred the shares of its subsidiary company that operates traditional Chinese medicine products, further focusing on innovative medicine business. Johnson&Johnson’s new cancer drug, Edatinib, has been approved for marketing in China Johnson&Johnson announced that ...
- Source: drugdu
- 357
- January 15, 2025
United Imaging Medical, there are big moves in North America

On January 9, 2025, United Imaging Healthcare officially signed an agreement to significantly expand its production and office space in the Greater Houston area. The new location in Pirlan, Texas will expand the manufacturing area of the company’s North American headquarters on Kirby Drive to more than three times its original size, and achieve an overall facility area growth of more than twice. The existing production facilities of Lianying Medical have only been in operation for over four years. 01. Internationalization Journey Lianying Medical has always been committed to internationalization, and its North American journey began more than a decade ago: In 2013, United Imaging Medical established a research and development center in Houston, USA. In 2018, United Imaging Medical participated in the annual meeting of the North American Society of Radiology and entered the North American market, with Houston becoming its regional headquarters. In 2020, the North American headquarters ...
- Source: drugdu
- 358
- January 15, 2025
Hengrui Pharmaceutical’s anti-PCSK9 monoclonal antibody has been approved for market, making it the 7th domestic product!

On January 10th, the latest announcement on the NMPA official website showed that Hengrui Pharmaceutical’s injection of Ruika Xidan Kang has been approved for marketing. The indications for this drug are: for adult patients, on the basis of controlling diet, it can be used alone or in combination with statins for other lipid-lowering therapies. It is suitable for patients with primary hypercholesterolemia (including heterozygous familial and non familial) and mixed dyslipidemia who still cannot achieve the target level of low-density lipoprotein cholesterol (LDL-C) after receiving moderate or higher doses of statins; Meanwhile, for adult patients with non familial hypercholesterolemia and mixed dyslipidemia, it can also be used as a monotherapy option to effectively reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and apolipoprotein B (ApoB) levels. Recaticimab (SHR-1209) is an anti-PCSK9 monoclonal antibody developed by Hengrui Pharmaceutical. The drug can increase the expression of LDLR on the surface of liver ...
- Source: drugdu
- 354
- January 15, 2025
Harbour Biomed Pharmaceuticals Signs Exclusive Licensing Agreement

On January 12, Harbour Biomed Pharmaceuticals (02142) announced that it has signed an exclusive licensing agreement with Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. and Windward Bio AG for HBM9378/SKB378. According to the agreement, the licensor will grant Windward Bio a global exclusive license to manufacture, develop, use, promote, sell, promise to sell, import, and otherwise commercialize HBM9378/SKB378 outside of Greater China and several Southeast Asian and Middle Eastern countries. Under the agreement, the licensor has the right to receive up to a total of $970 million in upfront and milestone payments, as well as tiered royalties ranging from single-digit to double-digit percentages of net sales. The signing of this agreement is expected to help integrate the R&D, production, and commercialization capabilities of the licensor and Windward Bio, bringing HBM9378/SKB378 to the global market. https://finance.eastmoney.com/a/202501123294354429.html
- Source: drugdu
- 242
- January 15, 2025
TopAlliances’ Dydrogesterone Tablets Approved for General Use

Beijing Business News (Reporter Ding Ning) – On the evening of January 12, TopAlliances (688180) announced that its wholly-owned subsidiary, Shanghai Wangshi Biopharmaceutical Technology Co., Ltd., has received a “Drug Supplement Application Approval Notice” issued by the National Medical Products Administration (NMPA). The hydrochloride of Dydrogesterone Tablets (brand name: Mindev) for the treatment of adult patients with mild to moderate COVID-19 infection has been approved by the NMPA, transitioning from conditional approval to general approval. https://finance.eastmoney.com/a/202501123294345292.html
- Source: drugdu
- 255
- January 15, 2025
National Center for Nanoscience and Technology has made progress in the research of universal tumor preventive nano vaccines

Recently, the team of Zhao Ruifang and Nie Guangjun from the National Center for Nanoscience and Technology, in collaboration with the team of Han Bing from Peking University School of Stomatology, have made new progress in the research of developing universal tumor preventive nano vaccines. The relevant research results were published online in Nature Biomedical Engineering (Nature Biomedical Engineering, 2024, DOI: 10.1038/s41551-024-01309-0) with the title of Potent prophylactic cancer vaccines harnessing surface antigens shared by tumour cells and induced pluripotent stem cells. By 2030, the number of new cases of malignant tumors worldwide will reach 22 million per year, and the huge population of malignant tumor patients will bring great pressure to society. In order to reduce the burden of cancer, research on tumor preventive vaccines is in full swing. In recent years, HPV and HBV vaccines have successfully reduced the incidence of cervical cancer and liver cancer related to ...
- Source: drugdu
- 265
- January 15, 2025
Kelun Biotech’s new ADC drug “Bodu Trastuzumab” has been approved for marketing with a new indication

On January 8, the CDE official website announced that the second indication application for the Class 1 new drug Bodu trastuzumab injection submitted by Kelun Biotech has been accepted for the treatment of adult patients with HER2-positive unresectable or metastatic breast cancer who have previously received at least one anti-HER2 treatment. Bodu trastuzumab is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2) developed by Kelun Biotech (formerly known as A166). This is the second NDA for A166. According to Kelun Biotech’s official website, based on the results of the primary analysis, A166 has reached the primary endpoint of its key Phase 2 trial for 3L+ advanced HER2-positive breast cancer and submitted its first marketing application to NMPA in May 2023. This is the second marketing application for the product, and the indication is for 2L+ advanced HER2-positive breast cancer. In addition, A166 has also conducted Phase ...
- Source: drugdu
- 206
- January 15, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.